GT Biopharma receives FDA clearance for GTB-5550 cancer treatment trial Feb 3, 2026 08:32AM
GT Biopharma (GTBP) files for 22.69M share offering by selling stockholders Jan 21, 2026 04:18PM
GT Biopharma submits IND application for solid tumor cancer treatment Jan 15, 2026 08:32AM
GT Biopharma advances phase 1 trial for blood cancer treatment Nov 19, 2025 08:00AM
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials Nov 19, 2025 08:00AM


Oct 24, 2025 04:20PM GT Biopharma (GTBP) files for 14.59M share offering by selling stockholders
Jun 13, 2025 09:02AM GT Biopharma (GTBP) Appoints Presents Data Supporting Rademikibart
May 19, 2025 09:05AM GT Biopharma (GTBP) advances GTB-3650 Phase 1 trial
May 15, 2025 09:02AM GT Biopharma (GTBP) Appoints Andrew Ritter to its Board
May 14, 2025 07:02AM GT Biopharma (GTBP) Appoints Hilary Kramer to its Board
Feb 25, 2025 02:00PM GT Biopharma (GTBP) Announces Exercise of Warrants
Feb 25, 2025 07:00AM GT Biopharma (GTBP) Requests Withdrawal of Form S-1 Registration Statement
Jan 27, 2025 07:02AM GT Biopharma (GTBP) Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
Dec 2, 2024 03:10AM Roth/MKM Starts GT Biopharma Inc. (GTBP) at Buy
Aug 15, 2024 08:06AM GT Biopharma (GTBP) Misses Q2 EPS by 217c
Jun 27, 2024 09:17AM GT Biopharma (GTBP) Announces FDA Clearance of Investigational NDA for GTB-3650
Jun 20, 2024 06:07AM GT Biopharma (GTBP) Files for 740K Share Offering by Selling Stockholders